Skip to content

Remedium Bio

1 viewer · 30d

Total raised

$1.5M

+$1.5M this year

1 filing since 2026 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $1.5M
ROUNDS
1
INVESTORS
1
FOUNDED
N/A
HQ
Needham, MA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Remedium Bio is a clinical-stage biotechnology company developing gene therapies for chronic diseases with large patient populations. Its Prometheus adjustable gene therapy platform is designed to replace repeated subcutaneously administered protein treatments with a single, dose-adjustable injection, using established AAV and lipid nanoparticle delivery vectors. Its pipeline spans endocrinology (obesity and Type 2 diabetes), neurology (ischemic stroke), and rheumatology (an FGF18 gene therapy for osteoarthritis intended to regenerate cartilage). The company was founded in 2020 and is based in the Boston area, with the Form D filed from Needham, Massachusetts.

What sets it apart

Dose adjustability — the Prometheus platform is built so a single gene therapy injection can be titrated up or down after administration, which is the central limitation of conventional one-and-done gene therapy, and it does so using clinically validated targets and established AAV/LNP vectors rather than novel delivery chemistry.

Funding history

1 round
EquityMay 6, 2026
Form D
+$1.5M$1.5M total

Latest SEC filings

via EDGAR · CIK 0001892414
Form D · May 6, 2026View on EDGAR

Products

1 tracked

Prometheus adjustable gene therapy platform

Gene therapy platform

A gene therapy platform delivering therapeutic genes via adeno-associated virus (AAV) and lipid nanoparticle (LNP) vectors in a single injection whose dose can be adjusted, intended to replace ongoing subcutaneous protein therapy with one durable, localized treatment.

  • Single-injection, dose-adjustable gene therapy
  • Uses established AAV and lipid nanoparticle delivery vectors
  • Localized and durable administration replacing repeated subcutaneous protein dosing
  • Applied to clinically validated targets rather than novel biology

Links

WebsiteLinkedInSEC EDGAR filings